GSK

GSK forms new deal with CureVac to make Covid variant vaccines

by

GSK strikes £132m deal with CureVac to develop vaccines for Covid variants as it reveals lacklustre annual results A total of £132m will be invested by GlaxoSmithKline into CureVac’s research Demand for GSK-made pain relief and digestive health products grew strongly GSK’s largest division, Pharmaceuticals, saw its sales drop 3% to £17.1bn  By Harry Wise … Read more

GSK Covid vaccine is delayed

by

GSK Covid vaccine is delayed: British pharmaceutical giant GlaxoSmithKline that is due to supply 60m doses of jab to Britain announces hold-up after ‘insufficient trial responses’ in elderly The UK in July secured 60million doses of the treatment among other jabs  Any Sanofi/GSK jab will now not likely be ready before the end of 2021  … Read more

British drug giants Astrazeneca and GSK still in race for a Covid jab

by

British drug giants Astrazeneca and Glaxosmithkline still in the race for a Covid jab By Matt Oliver For The Daily Mail Published: 21:53 GMT, 9 November 2020 | Updated: 21:53 GMT, 9 November 2020 Britain’s two biggest drugs companies are also developing Covid-19 vaccines. Potential jabs are being tested by FTSE 100 giants Astrazeneca and … Read more

GSK gears up for trials as it pushes ahead with three possible Covid-19 vaccines

by

GSK gears up for trials as it pushes ahead with three possible Covid-19 vaccines and two antibody treatments The British drugs group is also shipping record amounts of flu jabs  GSK warned that the pandemic continued to disrupt other parts of its business  But the firm said it would still pay out a dividend, expected … Read more

Chief Scientific Officer Sir Patrick Vallance has £600,000 of shares in vaccine maker GSK

by

Conflict of interest row as it emerges Chief Scientific Officer Sir Patrick Vallance has £600,000 of shares in vaccine maker contracted to make UK’s coronavirus jabs Sir Patrick was president of multinationals drugs giant GSK from 2012 to 2018 Chief Scientific Adviser holds a deferred bonus of 43,111 shares worth £600,000 He has already cashed in … Read more

UK Government signs deal with drugs giant GSK for 60 million doses of potential coronavirus vaccine

by

University of Oxford Oxford University academics began developing the ChAdOx1 nCoV-19 vaccine in January. It is now named AZD1222, after the researchers signed a manufacturing partnership with pharmaceutical giant AstraZeneca. Human trials started on April 23 and they are now in the final phase, with trials being carried out in the UK, Brazil and South … Read more

GSK boss sees no mass-produced COVID-19 vaccine until late next year

by

World’s largest vaccine maker GSK says there will be no mass coronavirus jab until late next year – as Pfizer says its COVID-19 jab could be ready by this autumn GSK’s chief executive said millions of doses would not be made until late 2021  Emma Walmsley, the CEO, said that an 18-month time line was … Read more

GSK, Sanofi strike deal to develop COVID-19 vaccine

by

Drugs giants GSK and Sanofi team up to create a coronavirus vaccine and hope to be able to produce tens of millions of doses by the middle of 2021 GlaxoSmithKline and Sanofi will join forces to speed up production of a vaccine Sanofi’s flu vaccine will be added to GSK’s booster to make doses last … Read more